

Catalog Number: 230-30162

**Recombinant SARS-CoV-2, S1 Subunit Protein (RBD)****Source**

|                         |   |
|-------------------------|---|
| <b>Species</b>          | SARS-CoV-2  |
| <b>Accession Number</b> | QHD43416  |
| <b>Expressed Region</b> | Arg319-Phe541   |
| <b>Synonyms</b>         | Spike protein, S Protein, S1 Subunit, Host Cell Receptor Binding Domain (RBD) |

**Preparation**

|                             |  |
|-----------------------------|--|
| <b>Expression System</b>    | Human embryonic kidney 293 (HEK293) cells  |
| <b>Tag</b>                  | C-terminal his-tag   |
| <b>Purification</b>         | His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC)  |
| <b>Purity</b>               | >95 %  |
| <b>Purity Determined By</b> | SDS-PAGE under reducing conditions and visualized by Coomassie blue staining   |
| <b>Molecular Weight</b>     | Recombinant protein product has a calculated molecular mass of 25 kDa. Due to the abundant glycosylation, it migrates as approximately 30 kDa protein bands in SDS-PAGE under DTT, beta-mercaptoethanol reducing conditions. See deglycosylation analysis image below. |

**Protein Specifications**

|                                 |   |
|---------------------------------|---|
| <b>Format</b>                   | Liquid  |
| <b>Formulation</b>              | Supplied as a 0.2 um filtered solution in PBS (pH 7.4)  |
| <b>Concentration</b>            | Lot specific (see the label on the vial), determined by BCA protein assay   |
| <b>Recommended Applications</b> | Lateral flow, indirect ELISA, sandwich ELISA, glycosylation analysis, binding assay, antibody generation, hybridoma screening, western blotting, biotin/dye/bead conjugation, binder selection, crystallization, and vaccine development. |


**SDS-PAGE Image**

Figure 1. Deglycosylation of purified recombinant proteins. Purified proteins were untreated (Lane 2) or treated with Protein Deglycosylation Kit under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one major band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated.

Lane 1: Protein standard ladder (kDa)

Lane 2: Untreated protein under reducing conditions

Lane 3: Treated protein with deglycosylation enzymes under native conditions

Lane 4: Treated protein with deglycosylation enzymes under reducing conditions.

## Shipping

Ice packs

## Storage/Stability

Upon arrival, the protein may be stored for 2 weeks at 4 °C. For long term storage, it is recommended to store at -20 °C or -80 °C in appropriate aliquots. Avoid repeated freeze-thaw cycles.

This product is furnished for LABORATORY RESEARCH USE ONLY.

Not for diagnostic or therapeutic use.